Noble Financial Remains a Buy on TherapeuticsMD (TXMD)
Noble Financial analyst Ahu Demir reiterated a Buy rating on TherapeuticsMD (TXMD) yesterday and set a price target of $13. The company’s shares closed yesterday at $2.71, close to its 52-week low of $2.21.
According to TipRanks.com, Demir is a 4-star analyst with an average return of 33.2% and a 42.9% success rate. Demir covers the Healthcare sector, focusing on stocks such as Dyadic International, Electrocore Llc, and TrovaGene.
Currently, the analyst consensus on TherapeuticsMD is a Strong Buy with an average price target of $9.17, representing a 238.4% upside. In a report issued on June 11, Oppenheimer also maintained a Buy rating on the stock with a $10 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.34 and a one-year low of $2.21. Currently, TherapeuticsMD has an average volume of 3.36M.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TXMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.